EFV600mg+FTC200mg+TDF300mg tabs/PAC-30

Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg, (equivalent to 245mg Tenofovir disoproxil), film coated tablets, bottle pack of 30
Indicative Price : Upon Request
Disclaimer: The images shown are for illustration purposes only and may not be an exact representation of the product. “No Generic Photo Available" means that there is not an image available for this product.

NOTE: The description below is for a standard product. It is not specific to patent status and pricing policies that may apply at country level. This information is available on request from Supply Division: Contact: supply@unicef.org

General Description:
Efavirenz 600mg + Emtricitabine 200mg + Tenofovir Disoproxil Fumarate 300mg, equivalent to 245mg Tenofovir Disoproxil, film coated tablet, pack of 30 tablets

Technical Specifications:
Each film coated tablet contains Efavirenz 600mg and Emtricitabine 200mg and Tenofovir Disoproxil Fumarate 300mg, equivalent to 245mg Tenofovir Disoproxil as fixed dose combination.

Therapeutic class:
Efavirenz is a Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Emtricitabine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Tenofovir is a Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

Standard shelf life:
2 years (24 months)

Other available formulations:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.

Guidelines for use:
For more details, please click the links listed below:

WHO treatment guidelines


WHO Essential Medicines Library

or your regional national guidelines

For details about paediatric dosage schemes, please click the links listed below:


WHO Generic tool for assessing paediatric ARV dosing

Management of HIV-1 infection in adults as a complete regimen or in combination with other antiretroviral drugs. By mouth (oral) PO.

Store below 30ºC (86ºF), in a tightly closed container.
Pack should come with desiccant
Keep out of reach and sight of children.

Dispensing instructions:
Dispense in original container. Do not repack.
To be taken on an empty stomach.
Advise patient to take the medicine at bedtime especially in the first 2-4 weeks to reduce CNS side effects.

Regulatory Status:
For latest updates, please click the links listed below:

List of WHO Prequalified Medicines

List of USFDA approved and tentatively approved items

Related Products